Rennie ICE 680 mg/ 80 mg Chewable Tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Calcium carbonate; Heavy magnesium carbonate

Available from:

Bayer Limited

ATC code:

A01AC01; A02AA01; A02AX

INN (International Name):

Calcium carbonate; Heavy magnesium carbonate

Dosage:

680 mg/80 milligram(s)

Pharmaceutical form:

Chewable tablet

Prescription type:

Product not subject to medical prescription

Therapeutic area:

triamcinolone; magnesium carbonate; Antacids, other combinations

Authorization status:

Not marketed

Authorization date:

2011-01-28

Patient Information leaflet

RESTRICTED
Package leaflet: Information for the user
Rennie
®
ICE
680mg
/
80mg CHEWABLE TABLETS
Calcium carbonate and Magnesium carbonate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist has told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not listed in this
leaflet. See section 4.
-
You must talk to a doctor if you do not feel better or if you
feel worse after 14 days.
WHAT IS IN THIS LEAFLET
1.
WHAT RENNIE
® ICE IS AND WHAT IT IS USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE RENNIE
® ICE
3.
HOW TO TAKE RENNIE
® ICE
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE RENNIE
® ICE
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
1. WHAT RENNIE
® ICE IS AND WHAT IT IS USED FOR
RENNIE
® ICE is an antacid tablet which relieves stomach upset due to
excess acid and heartburn (acid indigestion). Each tablet contains two
antacids – calcium carbonate and magnesium carbonate – that work
quickly and effectively to neutralise excess acid in the stomach.
Through this neutralisation they protect the stomach and the food pipe
against damaging effects of the excess acid. You must talk to a doctor
if you do not feel better or if you feel worse after 14 days.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE RENNIE
® ICE
DO NOT TAKE RENNIE
® ICE

If you have severe kidney disease or suffer from kidney stones.

If you have high calcium levels in the blood, kidneys or urine.

If you have low phosphate levels in the blood.

If you are allergic to calcium carbonate, magnesium carbonate or any
of the other ingredients of this medicine (listed in section 6).
WARNINGS AND PRECAUTIONS
Consult your doctor before taking Rennie
®
ICE if you have any kidney
problems.
As with other antacid p

Summary of Product characteristics

Health Products Regulatory Authority
05 December 2022
CRN00D655
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Rennie ICE 680 mg/ 80 mg Chewable Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
Calcium carbonate 680 mg (272 mg elemental calcium)
Heavy Magnesium Carbonate 80 mg (20 mg elemental magnesium)
Excipient(s) with known effect:
Sucrose 475 mg
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Chewable Tablet.
Creamy white square tablets with occasional slight speckling with
concave surfaces engraved ‘Rennie’ on both faces with odour
of mint.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For relief of stomach upsets due to hyperacidity and heartburn.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Tablets to be taken orally, sucked or chewed.
Adults: One or two tablets to be sucked or chewed as required, to a
maximum of eleven tablets a day and should not be taken
continuously for longer than 2 weeks.
Paediatric population: Not recommended for use in children and
adolescents below age 18 due to a lack of sufficient data on
safety or efficacy
Elderly persons:
No special dosage regimen is required, but care should be taken to
observe the contraindications and warnings.
Method of administration
For oral use.
4.3 CONTRAINDICATIONS
Rennie ICE should not be administered in the following cases:
• Hypersensitivity to the active substances or to any of the
excipients listed in section 6.1.
• Hypercalcaemia, hypercalciuria and/or conditions resulting in
hypercalcaemia e.g sarcoidosis
• Nephrolithiasis due to calculi containing calcium deposits
• Severe renal insufficiency
Health Products Regulatory Authority
05 December 2022
CRN00D655
Page 2 of 5
• Hypophosphatemia
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Prolonged use should be avoided. Do not exceed the stated dose and if
symptoms persist, after 7 days, further medical advice
should be sought.
Caution should generally be exercised in the case of patients